JMSACL (Journal of Mass Spectrometry & Advances in the Clinical Lab)’s Post

Source: Clinica chimica acta; international journal of clinical chemistry 3-O-methyldopa (3-OMD) is a promising biomarker for diagnosing high-risk neuroblastoma (NB). A method using LC-HRMS for measuring 3-OMD from dried plasma microsamples was developed and validated, showing high accuracy and reproducibility. Significant differences in 3-OMD levels were found across NB stages, and ROC analysis demonstrated its effectiveness in identifying high-risk patients. The method enhances future multi-site studies and allows for easy sample transport and storage.

Source: Bioinformatics (Oxford, England) MSIreg: R package for coregistration of mass spectrometry (MS) and H&E images, aiding pathologists in tissue analysis. It addresses challenges like aspect ratio and resolution differences without landmarks. Evaluated on six case studies, available open-source at GitHub.

Source: Clinical chemistry Mass spectrometry enhances diagnostic precision for free light chains.

Source: Bioanalysis Immunocapture mass spectrometry has evolved from chemical toxicology to focus on pharmacokinetics, biomarkers, and diagnostics. Key benefits include distinguishing molecular subtypes. Future research will target diverse analytes and enhance methodologies for faster, more reliable analyses through automation and multiplexing.

Source: Journal of proteome research Study on RasV12-induced GBM in Drosophila reveals novel mitochondrial proteins linked to tumor dynamics. Identified three DAPs via HRMS: Q9VHD2, Q04448, P20477, validated by qRT-PCR. Findings suggest mitochondrial regulators like Drp1 and Parkin are involved in GBM progression.

Source: Frontiers in chemistry Novel rhodamine B probe (RBTPA) enables rapid amino acid detection via fluorescence spectrum-mass spectrometry. Optimal identification occurs at pH 3, with significant UV absorption and fluorescence intensity changes. Binding structures analyzed by mass spectrometry reveal two isomers responsive to aldehyde and imine groups.

Source: Analytical chemistry Gabor Transform-based software quantifies therapeutic monoclonal antibodies (t-mAbs) in serum, improving sensitivity and specificity compared to traditional methods. This study compares results from GT-based iFAMS Quant+ using Agilent 6545XT to Mayo Clinic's method with Thermo Q Exactive Plus, showing excellent agreement and advantages in characterizing interferents.

Source: Molecules (Basel, Switzerland) Developed a rapid LC-MS/MS method for quantifying fluoxetine in human plasma using protein precipitation. Optimized parameters: methanol and ammonium formate mobile phase, 4 min run time. Validated with LLOQ 0.25 ng/mL, R² = 0.999. Fluoxetine stable at various conditions. Applied in pharmacokinetic study with nine volunteers, useful for routine and bioequivalence analyses.

Source: Journal of clinical medicine GC-MS breath analysis for chronic coronary syndrome (CCS) assessed VOCs from exhaled air. Study with 23 patients showed 91% sensitivity for non-revascularization and 58% specificity for revascularization. Identified 36 VOCs, suggesting GC-MS as a potential non-invasive diagnostic tool for CCS. Further validation with larger cohorts needed.

Source: International journal of molecular sciences Lipidomic study of serum from 30 schizophrenia patients and 31 controls using LC-HRMS revealed no clear group separation but identified 49 differential lipids in male patients and 60 in female patients. Altered lipid metabolism, particularly in glycerophospholipids, sphingolipids, glycerolipids, and fatty acids, was noted, with common lipids Cer 34:2, Cer 34:1, LPC 16:0, and TG 48:2 showing increased levels in patients. Findings highlight metabolic pathways' role in schizophrenia.